indazoles has been researched along with Hypertension in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.52) | 18.7374 |
| 1990's | 3 (4.55) | 18.2507 |
| 2000's | 12 (18.18) | 29.6817 |
| 2010's | 47 (71.21) | 24.3611 |
| 2020's | 3 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Domchek, SM; Donze, A; Gosselin, MK; Karasic, T; Massa, R; Mick, R; O'Hara, M; Onyiah, C; Reiss, KA; Schneider, C; Teitelbaum, U; Tondon, R; Vonderheide, RH | 1 |
| Anttila, M; Åvall Lundqvist, E; Birrer, MJ; Bjørge, L; dePont Christensen, R; Dimoula, M; Hietanen, S; Krog Vistisen, A; Lindahl, G; Lund, B; Mäenpää, JU; Malander, S; Mirza, MR; Nyvang, GB; Peen, U; Roed, H; Staff, S; Werner, TL; Ør Knudsen, A | 1 |
| Brown, JN; Hammond, JM; Lee, S; Sneed, GT | 1 |
| Bharathan, R; Chuai, Y; Dai, G; Li, Y; Otter, SJ; Rizzuto, I; Stewart, A; Wang, A; Zhang, X | 1 |
| Anandappa, G; Boink, Y; Bond, SJ; Brune, C; Cheriyan, J; Gajendragadkar, P; Hubsch, A; Jodrell, DI; Mäki-Petäjä, KM; McEniery, CM; McGeoch, A; Meyer, PAR; Mir, F; Ramenatte, N; Santos Franco, S; Schönlieb, CB; Wilkinson, IB; Yang, LL | 1 |
| Ali, A; Bopp, C; Chen, Q; Clemas, J; Cully, D; Duffy, R; Hoyt, SB; London, C; MacNeil, D; McMasters, D; Ren, N; Salituro, G; Sok, A; Struthers, M; Tang, W; Tata, J; Taylor, J; Tung, E; Ujjainwalla, F; Verras, A; Wisniewski, T; Xiong, Y; Zhou, G | 1 |
| Azad, NS; Gallagher, D; O'Connor, A; Ohaji, C; Rosner, G; Sartorius-Mergenthaler, S; Shroff, RT; Subbiah, V; Yarchoan, M; Zahurak, ML; Zinner, R | 1 |
| Antunes, E; Mónica, FZ | 1 |
| Bista, M; Collins, T; Gray, K; Hardy, C; Harmer, AR; Mettetal, JT; Skinner, M; Wang, H | 1 |
| Cefalu, M; Guo, A; Ho, TH; Janssen, P; Justice, C; Kempton, A; Makara, M; Smith, SA | 1 |
| Bastholt, L; Bengtsen, C; Jensen, BL; Jensen, NV; Madsen, K; Tinning, AR | 1 |
| Gunderson, CC; Matulonis, U; Moore, KN | 1 |
| O'Cearbhaill, RE | 1 |
| Barančík, M; Berenyiová, A; Dovinová, I; Hrabárová, E; Jansen, E; Kvandová, M; Majzúnová, M | 1 |
| Bauer, J; Grimm, D; Grosse, J; Infanger, M; Kopp, S; Krüger, M; Milling, RV; Wehland, M | 1 |
| Chen, D; Chen, YC; Du, GH; Fang, LH; Jiao, XZ; Niu, ZR; Xie, P; Yuan, TY; Zhang, HF | 1 |
| Jeon, SY; Lee, NR; Yim, CY | 1 |
| Carter, JJ; Cooper, SL; March, J; Woolard, J | 1 |
| Chen, JL; Hoffman, SE; Legasto, CS; McLaughlin, EM; Pisano, SG; Porter, K | 1 |
| He, AN; Qi, WX; Shen, Z; Yao, Y | 1 |
| Akaza, H; Chen, C; Kanayama, H; Kim, S; Naito, S; Ozono, S; Shinohara, N; Tarazi, J; Tomita, Y; Tsukamoto, T; Ueda, T; Uemura, H | 1 |
| Bodoky, G; Bodrogi, I; Csejtei, A; Dank, M; Géczi, L; Küronya, Z; Mangel, L; Maráz, A; Petrányi, A; Szûcs, M | 1 |
| Arruda, LS; Baum, M; Cisar, L; Kim, S; Motzer, RJ; Quinn, DI; Rini, BI; Roberts, WG; Rosbrook, B; Tarazi, J; Wood, LS | 1 |
| Chiu, YL; LoRusso, P; Ricker, JL; Xiong, H | 1 |
| Cacanyiova, S; Drobna, M; Kristek, F | 1 |
| Davis, ID; Deen, KC; Hawkins, RE; Sigal, E; Sternberg, CN | 1 |
| Cainap, C; Carlson, DM; Chen, PJ; Cheng, Y; Chung, IJ; El-Nowiem, S; Eskens, FA; Gorbunova, V; Huang, WT; Kang, YK; Kudo, M; McKee, MD; Pan, H; Qian, J; Qin, S; Ricker, JL; Toh, HC | 1 |
| Dai, YW; Huang, SC; Hwang, LL; Lee, YH; Li, TL; Tsai, MC | 1 |
| Chawla, SP; Dewji, R; Duffaud, F; Judson, I; Le Cesne, A; Litière, S; Marreaud, S; Papai, Z; Ray-Coquard, I; Schöffski, P; Sleijfer, S; van der Graaf, WT; Verweij, J | 1 |
| Belile, E; Bradford, C; Carey, T; Chepeha, DB; Dobrosotskaya, I; Eisbruch, A; Malloy, K; McKean, E; McLean, S; Moyer, J; Prince, M; Sacco, AG; Shuman, A; Spector, M; Swiecicki, PL; Wolf, GT; Worden, FP; Zhao, L | 1 |
| Kichenadasse, G; Mangoni, AA; Rowland, A; Sorich, MJ; Woodman, RJ | 1 |
| Carpenter, C; Figlin, RA; Goldstein, D; McCann, L; Pandite, L; Rosenberg, JE; Townsend, RR | 1 |
| Baculi, F; Bates, RJ; Bennett, B; Blease, K; Brown, H; Burnett, K; Celeridad, M; Chamberlain, P; Delgado, M; Ferguson, GD; Haelewyn, J; Hickman, M; Jackson, P; Jensen-Pergakes, K; LeBrun, L; Miyazawa, K; Nadolny, L; Nguyen, T; Packard, G; Pagarigan, B; Pierce, S; Plantevin-Krenitsky, V; Tang, Y; Tehrani, L; Torres, S; Xie, W; Xu, L | 1 |
| Griswold, J; Parekh, H; Rini, B | 1 |
| Araki, N; Boku, S; Goto, T; Hiraga, H; Honoki, K; Kawai, A; Matsumine, A; Nakamura, T; Nishida, Y; Sudo, A; Sugiura, H; Ueda, T; Yasuda, T; Yonemoto, T | 1 |
| Atreya, CE; Bergsland, EK; Cives, M; Coppola, D; Hwang, J; Kelley, RK; Morse, B; Nickerson, M; Strosberg, JR; Valone, T; Venook, A; Weber, T | 1 |
| Chi, Y; Cui, CX; Du, CX; Song, Y; Sun, Y; Sun, YK; Wang, JW; Yang, L; Zhang, W; Zhou, AP | 1 |
| Bono, P; Peltola, K; Penttilä, P; Poussa, T; Rautiola, J | 1 |
| Albert, DH; Banfor, PN; Cox, BF; Davidsen, SK; Franklin, PA; Fryer, RM; Gintant, GA; Segreti, JA; Widomski, DL | 1 |
| Dowlati, A; Gibson, DM; Hodge, JP; Hurwitz, HI; Merkle, EM; Pandite, L; Saini, S; Savage, S; Suttle, AB | 1 |
| Chen, CS; Goh, BC; Gupta, N; Hartono, S; Humerickhouse, R; Koh, TS; Lee, SC; Lim, R; Lim, SE; McKeegan, E; Ong, AB; Pradhan, R; Soo, R; Steinberg, J; Sukri, N; Thng, CH; Wong, CI; Wong, J; Yong, WP | 1 |
| Hashimoto, J; Itoh, K; Minami, H; Mukai, H; Mukohara, T; Nagai, S; Nakajima, H; Umeyama, Y | 1 |
| Altorki, N; Bauer, T; Felip, E; Grannis, FW; Guarino, MJ; Gurpide, A; Huff, A; Lane, ME; Lee, PC; Mitchell, JD; Ottesen, LH; Pass, H; Peylan-Ramu, N; Reeves, A; Roychowdhury, DF; Swann, RS; Tachdjian, S; Yankelevitz, DF | 1 |
| Arhancet, GB; Blinn, JR; Chen, X; Collins, JT; Dietz, JD; Garland, DJ; Heron, MI; Hockerman, SL; Homer, BL; Hu, X; Huang, HC; Long, SA; Mahoney, MW; McGee, KF; Meyers, MJ; Payne, MA; Reitz, DB; Rico, JR; Wendling, JM; Yang, S | 1 |
| Arumugham, T; Chiorean, EG; Dar, MM; Forman, K; Gainer, SD; Heath, EI; Hodge, JP; Lager, JJ; LoRusso, P; Malburg, L; Suttle, AB; Sweeney, CJ | 1 |
| Bair, AH; Bycott, P; Chan, S; Joy, AA; Kim, S; Liau, KF; Lluch, A; Rosbrook, B; Rugo, HS; Soulieres, D; Stopeck, AT; Verma, S | 1 |
| Steinman, TI | 1 |
| Cacanyiova, S; Kristek, F; Malekova, M; Ondrias, K | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Sun, YJ; Tang, LN; Yao, Y | 1 |
| Chien, SJ; Hsu, CN; Huang, CF; Huang, LT; Lin, YJ; Tain, YL | 1 |
| Barrios, CH; Chen, M; Davis, ID; Gladkov, OA; Hawkins, RE; Lee, E; Mardiak, J; McCann, L; Rubin, SD; Salman, P; Sternberg, CN; Szczylik, C; Wagstaff, J; Zarba, JJ | 1 |
| Andrews, L; Fishman, M; Gorbunova, V; Jonasch, E; Larkin, J; Negrier, S; Olivier, K; Pyle, L; Staehler, M; Wood, L | 1 |
| Ho Lee, B; Kang, NS; Lee, JH; Lee, JS; Oh, BK; Oh, KS; Park, CH; Seo, HW | 1 |
| Ndisang, JF; Wang, R; Zhao, W | 1 |
| Alonso, MJ; Balfagón, G; Márquez-Rodas, I; Rossoni, LV; Salaices, M; Vassallo, DV; Xavier, FE | 1 |
| Calderón-Cortés, E; Clemente-Guerrero, M; Cortés-Rojo, C; Gaona-Zamudio, FJ; Saavedra-Molina, A; Sierra-Campos, E; Villalobos-Molina, R | 1 |
| D'Alecy, LG; Linder, AE; Webb, RC; Weber, DS; Whitesall, SE | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Brown, RD; Carlström, M; Edlund, J; Larsson, E; Palm, F; Persson, AE; Sällström, J; Teerlink, T; Wåhlin, N | 1 |
| Fouyas, IP; Kelly, PA; Ritchie, IM; Whittle, IR | 1 |
| Casadei, B; Heinert, G; Paterson, DJ | 1 |
| Manning, RD; Meng, S; Tan, DY | 1 |
| Tojo, A; Welch, WJ; Wilcox, CS | 1 |
| Friebe, A; Koesling, D; Kreutz, R; Paul, M; Rothermund, L | 1 |
| Chai, CY; Su, CK; Wang, Y; Wu, WC | 1 |
| Bologna, E | 1 |
10 review(s) available for indazoles and Hypertension
| Article | Year |
|---|---|
The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Fatigue; Humans; Hypertension; Indazoles; Kidney Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2019 |
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bias; Brachytherapy; Combined Modality Therapy; Confidence Intervals; Female; Gastric Fistula; Gastrointestinal Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Fistula; Intestinal Perforation; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyridines; Pyrimidines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Thromboembolism; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult | 2021 |
Stimulators and activators of soluble guanylate cyclase for urogenital disorders.
Topics: Aging; Animals; Benzoates; Diabetes Complications; Enzyme Activators; Humans; Hypertension; Indazoles; Lower Urinary Tract Symptoms; Nitric Oxide; Obesity; Phosphodiesterase 5 Inhibitors; Pyrazoles; Pyridines; Reactive Oxygen Species; Risk Factors; Soluble Guanylyl Cyclase; Urinary Tract | 2018 |
Management of the toxicities of common targeted therapeutics for gynecologic cancers.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Autoimmune Diseases; Bevacizumab; Diarrhea; Epistaxis; Fatigue; Female; Genital Neoplasms, Female; Headache; Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Perforation; Molecular Targeted Therapy; Nausea; Neutropenia; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Proteinuria; Pyrimidines; Risk Assessment; Sulfonamides; Vomiting; Water-Electrolyte Imbalance | 2018 |
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
Topics: Anilides; Carcinoma, Neuroendocrine; Cardiotoxicity; Humans; Hypertension; Indazoles; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sulfonamides; Thyroid Neoplasms | 2018 |
Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Axitinib; Clinical Trials as Topic; Humans; Hypertension; Imidazoles; Incidence; Indazoles; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Risk | 2013 |
Axitinib for the treatment of metastatic renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy | 2016 |
Polycystic kidney disease: a 2011 update.
Topics: Antineoplastic Agents; Benzazepines; Curcumin; Everolimus; Gastrointestinal Agents; Glomerular Filtration Rate; Humans; Hypertension; Hypoglycemic Agents; Immunosuppressive Agents; Indazoles; Kidney; Metformin; Octreotide; Organ Size; Polycystic Kidney, Autosomal Dominant; Sirolimus; Sodium; Tolvaptan | 2012 |
Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Humans; Hypertension; Incidence; Indazoles; Neoplasms; Prospective Studies; Publication Bias; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Risk; Sulfonamides | 2013 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
19 trial(s) available for indazoles and Hypertension
| Article | Year |
|---|---|
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hypertension; Immune Checkpoint Inhibitors; Indazoles; Ipilimumab; Nivolumab; Pancreatic Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Topics: Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Endometrioid; Disease Progression; Female; Humans; Hypertension; Indazoles; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Progression-Free Survival; Proteinuria; Thrombocytopenia | 2019 |
Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cardiac Output; Endothelium, Vascular; Female; Hemodynamics; Humans; Hypertension; Indazoles; Male; Middle Aged; Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Vascular Resistance; Vascular Stiffness | 2021 |
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Axitinib; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Hypertension; Hypothyroidism; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proteinuria; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Circadian Rhythm; Cross-Over Studies; Drug Administration Schedule; Fatigue; Female; Food-Drug Interactions; Half-Life; Hand-Foot Syndrome; Humans; Hypertension; Indazoles; Male; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index | 2014 |
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anorexia; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hair Color; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Pyrimidines; Randomized Controlled Trials as Topic; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2014 |
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Axitinib; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Hypertension; Imidazoles; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Survival Rate | 2015 |
Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Pressure; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome | 2016 |
A phase II study of axitinib in advanced neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Colonic Neoplasms; Female; Humans; Hypertension; Imidazoles; Indazoles; Intestinal Neoplasms; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Protein Kinase Inhibitors; Rectal Neoplasms; Thymus Neoplasms; Treatment Outcome | 2016 |
Phase I trial of pazopanib in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Anorexia; Cohort Studies; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Hypertension; Indazoles; Male; Middle Aged; Nausea; Neoplasms; Pyrimidines; Sulfonamides; Vomiting | 2009 |
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Hypertension; Indazoles; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Axitinib; Biomarkers; Fatigue; Female; Humans; Hypertension; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Thyrotropin; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Fatigue; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypertension; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrimidines; Sulfonamides; Treatment Outcome | 2010 |
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Cohort Studies; Cross-Over Studies; Dietary Fats; Fatigue; Female; Food-Drug Interactions; Humans; Hypertension; Indazoles; Male; Middle Aged; Neoplasms; Pyrimidines; Sulfonamides | 2010 |
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypertension; Imidazoles; Indazoles; Middle Aged; Mucositis; Neoplasm Proteins; Neutropenia; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Taxoids; Thrombophilia | 2011 |
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cross-Over Studies; Diarrhea; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome | 2013 |
37 other study(ies) available for indazoles and Hypertension
| Article | Year |
|---|---|
Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension.
Topics: Animals; Antihypertensive Agents; Aromatase Inhibitors; Cell Line; Cricetulus; Cytochrome P-450 CYP11B2; Cytochrome P-450 CYP2D6 Inhibitors; Humans; Hypertension; Indazoles; Macaca mulatta; Male; Rats, Sprague-Dawley; Stereoisomerism; Steroid 11-beta-Hydroxylase | 2017 |
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Disease Progression; Disease-Free Survival; Drug Eruptions; Exanthema; Female; Humans; Hypertension; Indazoles; Male; MAP Kinase Kinase Kinases; Middle Aged; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Pyrimidinones; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Survival Rate; Thrombocytopenia | 2017 |
Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension.
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Blood Pressure; Dose-Response Relationship, Drug; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Hypertension; Imidazoles; Indazoles; Protein Kinase Inhibitors; Rats; Swine; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model.
Topics: Angiogenesis Inhibitors; Animals; Arterial Pressure; Body Weight; Carcinoma, Renal Cell; Cardiac Output; Disease Models, Animal; Echocardiography; Electrocardiography; Heart; Hypertension; Indazoles; Kidney; Kidney Neoplasms; Mice; Myocardium; Pyrimidines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sulfonamides; Vascular Endothelial Growth Factor A | 2018 |
Pazopanib-Induced Hypertension in Patients With Renal Cell Carcinoma Is Associated With Low Urine Excretion of NO Metabolites.
Topics: Administration, Oral; Aged; Carcinoma, Renal Cell; Cohort Studies; Denmark; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glomerular Filtration Rate; Hospitals, University; Humans; Hypertension; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitric Oxide; Prospective Studies; Pyrimidines; Risk Assessment; Sulfonamides; Time Factors | 2018 |
Using PARP Inhibitors in Advanced Ovarian Cancer.
Topics: Anemia; Creatinine; Drug Administration Schedule; Drug Interactions; Exanthema; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Heart Rate; Humans; Hypertension; Indazoles; Leukopenia; Mutation; Myelodysplastic Syndromes; Nasopharyngitis; Nausea; Ovarian Neoplasms; Piperidines; Pneumonia; Poly(ADP-ribose) Polymerase Inhibitors; Thrombocytopenia; Transaminases; Vomiting | 2018 |
ADMA, homocysteine and redox status improvement affected by 7-nitroindazole in spontaneously hypertensive rats.
Topics: Animals; Aorta; Arginine; Biomarkers; Disease Models, Animal; Enzyme Inhibitors; Heart Ventricles; Homocysteine; Hypertension; Indazoles; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Oxidation-Reduction; Rats, Inbred SHR | 2018 |
A novel hypertensive crisis rat model established by excessive norepinephrine infusion and the potential therapeutic effects of Rho-kinase inhibitors on it.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antihypertensive Agents; Blood Pressure; Hypertension; Indazoles; Male; Nitriles; Norepinephrine; Protein Kinase Inhibitors; Rats; Rats, Wistar; rho-Associated Kinases | 2019 |
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
Topics: Aged; Amlodipine; Angiogenesis Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Diabetic Nephropathies; Dihydropyridines; Drug Substitution; Edema; Everolimus; Humans; Hypertension; Indazoles; Kidney Failure, Chronic; Lung Neoplasms; Male; Nephrotic Syndrome; Nivolumab; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pneumonectomy; Protein Kinase Inhibitors; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib | 2019 |
Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats.
Topics: Animals; Arterial Pressure; Disease Models, Animal; Drug Administration Schedule; Humans; Hypertension; Indazoles; Male; Piperidines; Pyrimidines; Quinazolines; Random Allocation; Rats; Rats, Sprague-Dawley; Sulfonamides | 2019 |
Effect of Acid-Suppressive Strategies on Pazopanib Efficacy in Patients With Soft-Tissue Sarcoma.
Topics: Aged; Female; Humans; Hypertension; Indazoles; Male; Middle Aged; Progression-Free Survival; Proton Pump Inhibitors; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome | 2019 |
[First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Humans; Hungary; Hypertension; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; Treatment Outcome | 2013 |
Different effects of 7-nitroindazole and L-NAME administered both individually and together on the cardiovascular system of the rat.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Cardiomegaly; Carotid Arteries; Coronary Vessels; Disease Models, Animal; Enzyme Inhibitors; Heart Ventricles; Hypertension; Indazoles; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Rats, Inbred SHR; Rats, Wistar; Vascular Remodeling; Vasodilation; Ventricular Remodeling | 2015 |
Spontaneously hypertensive rats have more orexin neurons in the hypothalamus and enhanced orexinergic input and orexin 2 receptor-associated nitric oxide signalling in the rostral ventrolateral medulla.
Topics: Animals; Blood Pressure; Heart Rate; Hypertension; Hypothalamus; Indazoles; Male; Medulla Oblongata; Neurons; Neuropeptides; Nitric Oxide; Nitric Oxide Synthase Type I; Orexin Receptors; Orexins; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2015 |
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trial
Topics: Adult; Aged; Blood Pressure; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Hypertension; Indazoles; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Sarcoma; Sulfonamides | 2015 |
A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
Topics: Animals; Arthritis, Experimental; Basophils; Cell Line; Collagen; Crystallography, X-Ray; Dose-Response Relationship, Drug; Edema; Eosinophils; Female; HEK293 Cells; Humans; Hypertension; Indazoles; Inflammation; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Janus Kinase 2; Male; Neutropenia; Neutrophils; Protein-Tyrosine Kinases; Pyridines; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Receptors, Fc; Skin; Syk Kinase; Triazoles; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chemical and Drug Induced Liver Injury; Disease-Free Survival; Female; Fibrosarcoma; Humans; Hypertension; Indazoles; Japan; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Neurilemmoma; Pneumothorax; Product Surveillance, Postmarketing; Pyrimidines; Retrospective Studies; Sarcoma; Sarcoma, Synovial; Sulfonamides; Survival Analysis; Thrombocytopenia | 2016 |
[Relationship between treatment-related hypertension and therapeutic efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell carcinoma].
Topics: Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult | 2017 |
ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats.
Topics: Angiogenesis Inhibitors; Animals; Area Under Curve; Atrasentan; Blood Pressure; Dose-Response Relationship, Drug; Drug Interactions; Endothelin A Receptor Antagonists; Heart Rate; Hypertension; Indazoles; Male; Phenylurea Compounds; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Telemetry | 2009 |
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cell Line, Tumor; Chlorobenzenes; Crystallography, X-Ray; Humans; Hypertension; Indazoles; Indenes; Kidney Diseases; Male; Mineralocorticoid Receptor Antagonists; Models, Molecular; Molecular Conformation; Nitriles; Radioligand Assay; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship | 2010 |
Effects of chronic neuronal nitric oxide-synthase inhibition on arterial function and structure in spontaneously hypertensive rats.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Cardiomegaly; Enzyme Inhibitors; Heart; Hypertension; Indazoles; Male; Mesenteric Arteries; Nitric Oxide Synthase Type I; Norepinephrine; Rats; Rats, Inbred SHR | 2012 |
Aminoguanidine attenuates hypertension, whereas 7-nitroindazole exacerbates kidney damage in spontaneously hypertensive rats: the role of nitric oxide.
Topics: Amidohydrolases; Animals; Arginine; Blood Pressure; Citrulline; Guanidines; Hypertension; Indazoles; Kidney Diseases; Male; Nitric Oxide; Nitric Oxide Synthase Type I; Rats; Rats, Inbred SHR; Sodium Chloride, Dietary; Up-Regulation | 2013 |
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes.
Topics: Axitinib; Carcinoma, Renal Cell; Diarrhea; Dysphonia; Fatigue; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Nausea; Protein Kinase Inhibitors; Proteinuria; Vomiting | 2014 |
Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine (DW1865).
Topics: Actins; Animals; Antihypertensive Agents; Aorta, Thoracic; Cardiac Myosins; Cell Line; Hypertension; Indazoles; Male; Myosin Light Chains; Myosin-Light-Chain Phosphatase; Protein Kinase Inhibitors; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; rho-Associated Kinases; Triazines; Vasodilation | 2013 |
Selective regulation of blood pressure by heme oxygenase-1 in hypertension.
Topics: Animals; Blood Pressure; Culture Techniques; Cyclic GMP; Guanylate Cyclase; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Hemin; Hypertension; Indazoles; Male; Mesenteric Arteries; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Vasodilator Agents | 2002 |
Neurogenic nitric oxide release increases in mesenteric arteries from ouabain hypertensive rats.
Topics: Animals; Electric Stimulation; Enzyme Inhibitors; Hypertension; Indazoles; Male; Mesenteric Arteries; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitroarginine; Ouabain; Rats; Rats, Wistar; Tritium; Vasoconstriction | 2004 |
Functional characterization of brain mitochondrial nitric oxide synthase during hypertension and aging.
Topics: Aging; Animals; Arginine; Brain; Citrulline; Hypertension; Indazoles; Male; Mitochondria; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Oxygen Consumption; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Wistar | 2006 |
Altered vascular reactivity in mice made hypertensive by nitric oxide synthase inhibition.
Topics: Acetylcholine; Animals; Aorta; Blood Pressure; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Activators; Enzyme Inhibitors; Heart Rate; Hypertension; In Vitro Techniques; Indazoles; Male; Mice; Muscle Relaxation; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitroarginine; Nitroprusside; Phenylephrine; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2005 |
Role of nitric oxide deficiency in the development of hypertension in hydronephrotic animals.
Topics: Animals; Arginine; Blood Pressure; Disease Models, Animal; Diuresis; Enzyme Inhibitors; Hydronephrosis; Hypertension; Indazoles; Kidney; Kidney Cortex; Kidney Tubules, Proximal; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type III; Potassium; Rats; Rats, Sprague-Dawley; Sodium; Sodium Chloride, Dietary; Ureteral Obstruction | 2008 |
Cerebrovascular effects of nitric oxide manipulation in spontaneously hypertensive rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Autoradiography; Blood Pressure; Cerebrovascular Circulation; Disease Models, Animal; Hypertension; Indazoles; Infusions, Intravenous; Injections, Intravenous; Isotope Labeling; Male; Molsidomine; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Vasodilation; Vasodilator Agents | 1997 |
Hypercapnic cerebral blood flow in spontaneously hypertensive rats.
Topics: Animals; Blood Flow Velocity; Cerebral Cortex; Cerebrovascular Circulation; Enzyme Inhibitors; Hypercapnia; Hypertension; Indazoles; Indomethacin; Nitric Oxide Synthase; omega-N-Methylarginine; Oxygen; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Vasodilation | 1998 |
Role of neuronal nitric oxide synthase in Dahl salt-sensitive hypertension.
Topics: Animals; Blood Pressure; Diet, Sodium-Restricted; Enzyme Inhibitors; Glomerular Filtration Rate; Hypertension; Indazoles; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Rats; Rats, Inbred Dahl; Renal Circulation; Renin; Sodium; Sodium, Dietary | 1999 |
Roles of NO and oxygen radicals in tubuloglomerular feedback in SHR.
Topics: Animals; Cyclic N-Oxides; Feedback; Hypertension; Indazoles; Kidney Glomerulus; Kidney Tubules; Male; Nitric Oxide; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Spin Labels; Superoxide Dismutase; Superoxides; Tyrosine | 2000 |
Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats.
Topics: Animals; Blood Pressure; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Guanylate Cyclase; Hypertension; Indazoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Platelet Aggregation Inhibitors; Rats; Rats, Inbred WKY | 2000 |
The nNOS/cGMP signal transducing system is involved in the cardiovascular responses induced by activation of NMDA receptors in the rostral ventrolateral medulla of cats.
Topics: Animals; Blood Pressure; Bradycardia; Cats; Cyclic GMP; Enzyme Inhibitors; Excitatory Amino Acid Agonists; Female; Guanylate Cyclase; Heart Rate; Hypertension; Indazoles; Male; Medulla Oblongata; N-Methylaspartate; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Oxadiazoles; Quinoxalines; Receptors, N-Methyl-D-Aspartate; Signal Transduction | 2001 |
Influence of some drugs on platelet aggregation: a study in hypertensive patients.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents; Aspirin; Benzyl Compounds; Blood Cell Count; Blood Coagulation; Blood Platelets; Dimethylamines; Dipyridamole; Humans; Hypertension; In Vitro Techniques; Indazoles; Indomethacin; Phenylbutazone; Platelet Adhesiveness; Reserpine; Thrombosis; Time Factors | 1972 |